文献速递颈动脉与弓上血管

慢性抗血小板与抗凝药物对颈动脉内膜切除术后颈部血肿及围术期结局的影响

Effect of Chronic Antiplatelet and Anticoagulant Medication in Neck Hematoma and Perioperative Outcomes after Carotid Endarterectomy.
PubMed 文献 · Ann Vasc Surg · 2022-09-15

该回顾性分析纳入2015至2019年同一血管外科进行的304例颈动脉内膜切除术,评估术前5天内抗血栓药物与术后颈部血肿、卒中和死亡的关系。双联抗血小板和抗凝治疗未带来围术期获益,反而与严重血肿风险升高相关,而阿司匹林单药似乎是最安全的围术期抗血栓方案。

要点

  • 双联抗血小板和抗凝治疗未改善术后卒中结局,且与严重血肿风险升高相关。
  • 与阿司匹林相比,双联抗血小板组严重血肿相对风险RR 11.84(P=0.002)。
  • 严重颈部出血与充血性心力衰竭风险升高9.26倍及住院时间延长相关。

核心结论

  • 双联抗血小板和抗凝治疗在择期颈动脉内膜切除术后未带来更好的围术期结局,与颈部血肿风险增加相关,尤其严重出血,神经事件发生率相似且无死亡获益。
  • 阿司匹林单药似乎是择期颈动脉内膜切除术后最安全的围术期抗血栓方案。

研究设计与样本

  • 回顾性分析2015至2019年同一血管外科接受颈动脉内膜切除术的患者,共纳入304例颈动脉内膜切除术。
  • 识别术前5天内的抗血栓药物,通过单因素和多因素分析确定终点预测因素并校正混杂因素。

主要发现

  • 重要血肿发生率为8.22%,其中严重血肿(需手术探查)为4.93%。
  • 30天所有卒中发生率在有症状患者为2.94%,无症状患者为1.79%(P=0.51)。
  • 与阿司匹林相比,单用氯吡格雷或三氟柳的严重血肿相对风险RR 4.25(P=0.11),双联抗血小板组RR 11.84(P=0.002),抗凝组RR 8.604(P=0.02)。
  • 双联抗血小板和抗凝治疗在有症状或无症状患者中均未较阿司匹林单药提供术后卒中保护。
  • 无药物、双联抗血小板和抗凝组较阿司匹林组院内死亡率数值更高但无统计学显著性。

临床怎么用

  • 作者认为,阿司匹林单药似乎是择期颈动脉内膜切除术后最安全的围术期抗血栓方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A retrospective analysis of neck hematoma, stroke, and mortality after symptomatic and asymptomatic carotid endarterectomy (CEA) was conducted, to determine the most appropriate perioperative medication for these patients. Thirty-day outcomes of moderate and severe neck bleeding were also investigated. METHODS: Patients undergoing CEA in a Vascular Surgery department were analyzed (2015-2019). Preprocedure antithrombotic medication (from the 5 days prior to surgery) was identified. End point predictors were identified by univariate and multivariable analyses and adjusted for confounders. RESULTS: A total of 304 CEA were included. Almost half of the included patients (49.67%) were under low-dose aspirin, 17.55% other single antiplatelet agent, 12.59% dual antiplatelet therapy, 8.61% anticoagulation, and 10.92% no antithrombotic therapy. There was a 8.22% rate of important hematoma, including 4.93% severe (requiring surgical exploration) hematomas and a 30-day all-stroke incidence of 2.94% in symptomatic and 1.79% asymptomatic patients (P = 0.51). When compared to aspirin, severe hematoma was more prevalent with single clopidogrel or triflusal (relative risk [RR] 4.25, P = 0.11), dual antiplatelet group (RR 11.84, P = 0.002), and anticoagulation (RR 8.604, P = 0.02). Dual antiaggregation and anticoagulation did not confer postoperative stroke protection compared to single aspirin in either symptomatic or asymptomatic patients. Nonsignificant higher intrahospital mortality was noted in no medication, dual antiplatelet, and anticoagulation groups in contrast to aspirin. Severe neck bleeding was associated with increased congestive heart failure (9.26-fold, P = 0.03) and longer hospital stay (11.20 ± 24.69 days vs. 3.18 ± 4.79 with no bleeding, P < 0.001), with a tendency for higher hospital readmission at 30 days (4.66-fold, P = 0.13). Mortality and stroke rates were similar. CONCLUSIONS: Double antiaggregation and anticoagulation did not confer better perioperative outcomes after elective CEA in our study. These regimens were associated with an increased risk of neck hematoma, especially severe bleeding, with similar rates of neurologic events in both symptomatic and asymptomatic patients and no mortality benefit. Monotherapy with aspirin appears to be the safest perioperative antithrombotic regimen for elective CEA.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cruz Silva J, Constâncio V, Lima P, et al. Effect of Chronic Antiplatelet and Anticoagulant Medication in Neck Hematoma and Perioperative Outcomes after Carotid Endarterectomy. Ann Vasc Surg. 2022. PMID: 36116744. doi:10.1016/j.avsg.2022.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。